Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on LRMR stock, giving a Buy rating on March 25.
Joseph Schwartz’s rating is based on several promising developments for Larimar Therapeutics. The FDA has shown a willingness to consider skin frataxin levels as a novel surrogate endpoint, which could facilitate an Accelerated Approval pathway for the company’s treatment for Friedreich’s ataxia. This regulatory openness is a significant step forward and aligns with recent discussions with the company’s management, indicating a clearer path to market for their treatment.
Furthermore, despite ongoing discussions with the FDA regarding safety data, Larimar Therapeutics is taking proactive measures by amending study protocols to manage potential issues. The company’s strong financial position, with $183.5 million in cash and equivalents, provides a solid runway into the second quarter of 2026. These factors, combined with the potential for a valuable new treatment option not yet reflected in the company’s valuation, underpin Schwartz’s Buy rating.
In another report released on March 25, Citi also maintained a Buy rating on the stock with a $14.00 price target.
LRMR’s price has also changed dramatically for the past six months – from $6.410 to $2.280, which is a -64.43% drop .